Biosimilar Paradox: How Biosimilar Use Will Increase Patient and Healthcare Costs

Related

• 

  Expert Panel: Pegcetacoplan Safety

  Andre J. Witkin, MD

  David A. Eichenbaum, MD, FASRS

  Samuel Anthony Minaker, MD, MSc

  Janani Singaravelu, MS, MD

  Sunir J. Garg, MD, FACS, FASRS

  Annual Meeting Talks

  2024

• 

  Ranibizumab Induces Regression of Diabetic Retinopathy

  Charles C Wykoff, MD, PhD, FASRS

  Updates from the Field

  2016

• 

  Masked Safety Data from ZETA-1, an Ongoing 24-Week Phase 2 Clinical Trial of APX3330, an Oral Therapeutic Being Developed for the Treatment of Diabetic Retinopathy

  Michael J Allingham, MD, PhD

  Annual Meeting Talks

  2022